Silke Heidenreich

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Incidence, molecular and clinical characteristics of donor-derived hematologic malignancies after allogeneic stem cell transplantation for myeloid malignancies.

Incidence, molecular and clinical characteristics of donor-derived hematologic malignancies after allogeneic stem cell transplantation for myeloid malignancies.

Journal: Haematologica

Published: April 20, 2026

Erratum to: "Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation".

Erratum to: "Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation".

Journal: Haematologica

Published: March 01, 2026

Outcomes of allogeneic transplantation in blast-phase myeloproliferative neoplasms: one-third achieve long-term survival.

Outcomes of allogeneic transplantation in blast-phase myeloproliferative neoplasms: one-third achieve long-term survival.

Journal: Bone marrow transplantation

Published: November 13, 2025

Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis.

Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis.

Journal: Transplantation and cellular therapy

Published: October 03, 2025

Remission Status Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Harboring Single-Hit or Multi-Hit p53 Mutations Does Not Impact Outcome.

Remission Status Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Harboring Single-Hit or Multi-Hit p53 Mutations Does Not Impact Outcome.

Journal: Transplantation and cellular therapy

Published: August 18, 2025

Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation.

Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation.

Journal: Bone marrow transplantation

Published: March 25, 2025

Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT.

Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT.

Journal: Bone marrow transplantation

Published: March 25, 2025

Clearance of Driver Mutations after Transplantation for Myelofibrosis.

Clearance of Driver Mutations after Transplantation for Myelofibrosis.

Journal: The New England journal of medicine

Published: January 08, 2025

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Journal: Transplantation and cellular therapy

Published: December 08, 2024

Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation.

Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation.

Journal: Haematologica

Published: November 06, 2024

Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm.

Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm.

Journal: British journal of haematology

Published: October 20, 2024

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis.

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis.

Journal: American journal of hematology

Published: September 11, 2024

Showing 1-12 of 27

Last Updated: 09/26/2026